Cipla receives EIR for Invagen facility from USFDA

Cipla receives EIR for Invagen facility from USFDA

Cipla Ltd informed the exchanges today that United States Food and Drug Administration (USFDA) had conducted an inspection at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019. Further to the development, the company has received the Establishment Inspection Report (EIR), indicating closure of the inspection. 

The stock is trading marginally lower in trade today.

Stock view:
Cipla Ltd is currently trading at Rs463.80 down by Rs0.85 or 0.18% from its previous closing of Rs464.65 on the BSE.
The scrip opened at Rs466 and has touched a high and low of Rs466.95 and Rs459.45 respectively. So far 6,01,348 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs37,461.37cr.




About Gosip4U

Gosip4U is the digital wing of india - India's leading media and communications group with its interests spanning across country.

0 comments:

Post a Comment

Please add comment